Dilip Shanghvi
Health care

Dilip Shanghvi Net Worth

Dilip Shanghvi, born on October 01, 1955 in Amreli, Gujarat, India, is the founder and managing director of Sun Pharmaceutical Industries, the world's fifth largest generics maker and India's most valuable pharma outfit. He started the company in 1983 with a loan of $200 from his father and has grown it through a series of acquisitions, the largest of which was the purchase of Ranbaxy Laboratories for $4 billion in 2014. However, his fortune has declined in recent years due to manufacturing lapses at one of Sun's factories.
Dilip Shanghvi is a member of Health care

Age, Biography and Wiki

Birth Day October 01, 1955
Birth Place Amreli, Gujarat, India, India
Age 67 YEARS OLD
Birth Sign Scorpio
Residence Mumbai, India
Alma mater University of Calcutta
Occupation Founder and MD of Sun Pharmaceuticals
Spouse(s) Vibha Sanghvi
Children 2

💰 Net worth: $15.6 Billion (2024)

Dilip Shanghvi, considered a prominent figure in the healthcare industry in India, is widely recognized for his entrepreneurial success and leading the pharmaceutical company, Sun Pharmaceuticals Industries Ltd. His net worth is projected to reach an impressive $15.6 billion by 2024. Shanghvi's contributions to the healthcare sector have been instrumental in providing affordable and innovative medicines, thus playing a pivotal role in enhancing access to healthcare services across the country. His entrepreneurial journey and immense wealth underline his profound impact on the healthcare landscape of India.

2009 $3 Billion
2010 $4.6 Billion
2011 $6.1 Billion
2012 $7.4 Billion
2013 $9.4 Billion
2014 $12.8 Billion
2015 $20 Billion
2016 $16.7 Billion
2017 $13.7 Billion
2018 $11.44 Billion

Famous Quotes:

Our story is all about incremental growth. We"re not looking for big leaps; we prefer small jumps.

Biography/Timeline

1982

Shanghvi started Sun Pharmaceutical Industries with capital of ₹10,000 in 1982 at Vapi, with one psychiatry drug and a partner, Pradeep Ghosh. In 1997, Sun acquired Caraco Pharma, a loss-making American company, with the aim of expanding Sun's reach in the United States. Sun also acquired Israel's Taro Pharma in 2007. Shanghvi stepped down as chairman and CEO in 2012 and chose Israel Makov, formerly CEO of Teva Pharmaceuticals, as his successor; Shangvi became managing Director. In April 2014 Sun, Ranbaxy, and Daiichi Sankyo (the majority shareholder in Ranbaxy) agreed that Sun would acquire all outstanding shares of Ranbaxy for $3.2B in Sun stock and that Sun would take on $800M in Ranbaxy debt; the deal closed in March 2015 and made Sun the largest drug company in India and the fifth largest in the world, and made Daiichi the second largest shareholder in Sun.

2014

As of August 2014, he had a net worth of $17.2 billion.

Some Dilip Shanghvi images

About the author

Lisa Scholfield

As a Senior Writer at Famous Net Worth, I spearhead an exceptional team dedicated to uncovering and sharing the stories of pioneering individuals. My passion for unearthing untold narratives drives me to delve deep into the essence of each subject, bringing forth a unique blend of factual accuracy and narrative allure. In orchestrating the editorial workflow, I am deeply involved in every step—from initial research to the final touches of publishing, ensuring each biography not only informs but also engages and inspires our readership.